This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs.
intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic
cystoid macular edema (CME). Twenty consented patients with acute CME after
phacoemulsification cataract surgery with posterior chamber intraocular lens implantation
(PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three
monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3
months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically
in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening
of CME, combined with any of the following:
- Any increase in spectral domain ocular coherence tomography (OCT) central macular
thickness (CMT)
- Any observable fluid on OCT
- Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA).
Patients will be followed monthly through 12 months.